🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with Donald Trump are "fundamentally unstable." This comes after revelations that a much-touted deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, described as a "generational" achievement, remains an "statement of intent" without detailed provisions. Critics have noted that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for nothing more than a pledge from President Trump," said David Henig, a trade policy analyst. "History shows he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Worries have been amplified by Washington's recent decision to suspend the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US claimed a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions promised for British farmers as part of an May trade agreement have not been formally approved by the US, despite a fast-approaching January deadline. "It is our belief that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have admitted unease that the government's US-UK accords are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Government figures have downplayed the possibility of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is part and parcel of dealing with the Trump administration. However, they argue that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have emerged in carrying out the broader trade deal. Promised reciprocal agricultural allowances have failed to be approved, and the assurance to "eliminate duties on UK metals" has remains unmet, with tariffs remaining at 25%.

As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.